Bacterial enteric infections in children: Etiology, clinical manifestations and antimicrobial therapy

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 4, 2006, Pages 629-638

  Chao, Hsun Chin ^a   Chen, Chien Chang ^a   Chen, Shih Yen ^a   Chiu, Cheng Hsun ^b  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Antimicrobial therapy; Bacteria; Children; Enteric infection

Indexed keywords

ACTIVATED CARBON; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ATTAPULGITE; AZITHROMYCIN; BACTERIAL VACCINE; BISMUTH DERIVATIVE; BISMUTH SALICYLATE; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COLESTYRAMINE; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; KAOLIN PECTIN; MACROLIDE; METRONIDAZOLE; NALIDIXIC ACID; ORAL REHYDRATION SOLUTION; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL GENOME; BACTERIAL INFECTION; CAMPYLOBACTER; CHILD; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CHOLERA; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; DIARRHEA; DIETARY FIBER; DISEASE COURSE; DISEASE SEVERITY; DRUG INDICATION; ENTEROBACTER INFECTION; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTESTINE INFECTION; NONHUMAN; ORAL REHYDRATION THERAPY; PATHOGENESIS; REVIEW; RISK FACTOR; SALMONELLA; SALMONELLOSIS; SEQUENCE ANALYSIS; SHIGELLOSIS; TYPHOID FEVER; VACCINATION; YERSINIA ENTEROCOLITICA; YERSINIOSIS;

ANTI-BACTERIAL AGENTS; ANTIDIARRHEALS; BACTERIAL INFECTIONS; CHILD; DIARRHEA; FEVER; FLUID THERAPY; HUMANS;

EID: 33749516320     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.4.629     Document Type: Review

References (83)

1. Committee on Salmonella, Division of Biology and Agriculture of the National Research Council. An evaluation of the Salmonella problem. National Academy of Science, Washington DC, USA (1969).
2. Vandamme P, Falsen E, Rossau R et al. Revision of Campylobacter, Helicobacter, and Wolinella taxonomy: Recommendation of generic descriptions and proposal of Arcobacter gen. nov. Int. J. Syst. Bacteriol. 41, 88-103 (1991).
3. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 11, 142-201 (1998).
4. Giron JA, Jones T, Millan-Velasco F et al. Diffuse-adhering Escherichia coli (DAEC) as a putative cause of diarrhea in Mayan children in Mexico. J. Infect. Dis. 163, 507-513 (1991).
5. Cohen MB, Nataro JP, Bernstein DI, Hawkins J, Roberts N, Staat MA. Prevalence of diarrheagenic Escherichia coli in acute childhood enteritis: a prospective controlled study. J. Pediatr. 146, 54-61 (2005).
6. Rao PM, Rhea JT, Novelline RA, Mostafavi AA, McCabe CJ. Effect of computed tomography of the appendix on treatment of patients and use of hospital resources. N. Engl. J. Med. 338, 141-146 (1998).
7. Torrey S, Fleisher G, Jaffe D. Incidence of Salmonella bacteremia in infants with Salmonella gastroenteritis. J. Pediatr. 108, 718-721 (1986).
8. Khoshoo V, Raj P, Srivastava R, Bhan MK. Salmonella typhimurium-associated severe protracted diarrhea in infants and young children. J. Pediatr. Gastroenterol. Nutr. 10, 33-36 (1990).
9. Buchwald DS, Blaser MJ. A review of human salmonellosis: 11. Duration of excretion following infection with nontyphi Salmonella. Rev. Infect. Dis. 6, 345-356 (1984).
10. Wittler RR, Bass JW. Nontyphoidal Salmonella enteric infections and bacteremia. Pediatr. Infect. Dis. J. 8, 364-367 (1989).
11. Blaser MJ, Feldman RA. From the Centers for Disease Control. Salmonella bacteremia: reports to the Centers for Disease Control, 1968-1979. J. Infect. Dis. 143, 743-746 (1981).
12. Rabinowitz SG, MacLeod NR. Salmonella meningitis: a report of three cases and review of the literature. Am. J. Dis. Child. 23, 259-262 (1972).
13. Huang LT, Ko SF, Lui CC. Salmonella meningitis: clinical experience of third-generation cephalosporins. Acta Paediatr. 86, 1056-1058 (1997).
14. Nelson MR, Shanson DC, Hawkins DA, Gazzard BG. Salmonella, Campylobacter and Shigella in HIV-seropositive patients. AIDS 6, 1495-1498 (1992).
15. Wright J, Thomas P, Serjeant GR. Septicemia caused by Salmonella infection: an overlooked complication of sickle cell disease. J. Pediatr. 130, 394-399 (1997).
16. Stuart BM, Pullen RL. Typhoid: clinical analysis of three hundred and sixty cases. Arch. Intern. Med. 78, 629-661 (1946).
17. DuPont HL, Hornick RB, Dawkins AT, Snyder MJ, Formal SB. The response of man to virulent Shigella flexneri 2a. J. Infect. Dis. 119, 296-299 (1969).
18. Taylor D, Echeverria P, Pal T et al. The role of Shigella spp, enteroinvasive Escherichia coli and other enteropathogens as causes of childhood dysentery in Thailand. J. Infect. Dis. 153, 1132-1138 (1986).
19. Koster F, Levin J, Walker L et al. Hemolyticuremic syndrome after shigellosis: relation to endotoxemia and circulating immune complexes. N. Engl. J. Med. 298, 927-933 (1978).
20. Puylaert JB, Vermeijden RJ, van der Werf SD, Doornbos L, Koumans RK. Incidence and sonographic diagnosis of bacterial ileocaecitis masquerading as appendicitis. Lancet 2, 84-86 (1989).
21. Wong SN, Tam AY, Yien KY. Campylobacter infection in the neonate: case report and review of the literature. Pediatr. Infect. Dis. J. 9, 665-669 (1990).
22. Clausen CR, Christie DI. Chronic diarrhea in infants caused by adherent enteropathogenic Escherichia coli. J. Pediatr. 100, 358-361 (1982).
23. Slutsker L, Ries AA, Greene KD, Wells JG, Hutwagner L, Griffin PM. Escherichia coli O157:H7 diarrhea in the United States: clinical and epiderniologic features. Ann. Intern. Med. 126, 505-513 (1997).
24. Griffin PM, Ostroff SM, Tauxe RV et al. Illnesses associated with Escherichia coli O157:H7 infections: a broad clinical spectrum. Ann. Intern. Med. 109, 705-712 (1988).
25. Griffin PM, Bell BP, Cieslak PR et al. Large outbreak of Escherichia coli O157:H7 infections in the western United States: the big picture. In: Recent Advances in Verocytotoxin-producing Escherichia coli Infection. Karmali MA, Goglio AG (Eds). Elsevier Science BV, Amsterdam, The Netherlands, 7-12 (1994).
26. Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the haemolytic-uremic syndrome. N. Engl. J. Med. 333, 364-368 (1995).
27. Uc A, Mitros FA, Kao SC, Sanders KD. Pseudomembranous colitis with Escherichia coli O157:H7. J. Pediatr. Gastroenterol. Nutr. 24, 590-593 (1997).
28. Snyder JD, Wells JG, Yashuk J, Puhr N, Blake PA. Outbreak of invasive Escherichia coli gastroenteritis on a cruise ship. Am. J. Trop. Med. Hyg. 33, 281-284 (1984).
29. Pavia AT, Nichols CR, Green DP et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J. Pediatr. 116, 544-551 (1990).
30. Riley LW, Remis RS, Helgerson SD et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 308, 681-685 (1983).
31. Tarr PI, Neill MA, Clausen CR, Watkins SL, Christie DL, Hickman RO. Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J. Infect. Dis. 62, 553-556 (1990).
32. Pai M, Kang G, Raniakrishna BS et al. An epidemic of diarrhoea in south India caused by enteroaggregative Escherichia coli. Indian J. Med. Res. 106, 7-12 (1997).
33. Cobejic M, Miljkovic-Selimovic B, Paunovic-Todosijevic D et al. Enteroaggregative Eschedchia coli associated with an outbreak of diarrhoea in a neonatal nursery ward. Epidemiol. Infect. 117, 11-16 (1996).
34. Itoh Y, Nagano I, Kunishirna M, Ezaki T. Laboratory investigation of enteroaggegative Escherichia coli O untypeable: H10 associated with a massive outbreak of gastrointestinal illness. J. Clin. Microbiol. 35, 2546-2550 (1997).
35. Marks MI, Pai CH, Lafleur L, Lackman L, Hammerberg O. Yersinia enterocolitica gastoenteritis: a prospective study of clinical, bacteriologic and epidemiologic features. J. Pediatr. 96, 26-31 (1980).
36. Cover TI. Yersinia enterocolitica and Yersinia pseudotuberculosis. In: Infections of the Gastrointestinal Tract. Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL (Eds). Raven Press, NY, USA, 11-23 (1985).
37. Tacket CO, Davis BR, Carter GP, Randolph JF, Cohen ML. Yersinia enterocolitica pharymgitis. Ann. Intern. Med. 99, 40-42 (1983).
38. Hoogkamp-Korstanje JA, Stolk-Engelaar VM. Yersinia enterocolitica infection in children. Pediatr. Infect. Dis. J. 14, 771-775 (1995).
39. Borriello SE. Pathogenesis of Clostridium difficile infection. J. Antimicrob. Chemother. 41, 13-19 (1984).
40. Batts DH, Martin D, Holmes R, Silva J, Fekety FR. Treatment of antibiotic-associated Clostridium difficile diarrhea with oral vancomycin. J. Pediatr 97, 151-153 (1980).
41. Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann. Surg. 235, 363-372 (2002).
42. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol, 26, 273-280 (2005).
43. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin. Infect. Dis. 40, 265-272 (2005).
44. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353, 2433-2441 (2005).
45. Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J. Clin. Microbiol. 42, 1933-1939 (2004).
46. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmee M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J. Clin. Microbiol. 36, 2240-2247 (1998).
47. Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J. Med. Microbiol. 53, 887-894 (2004).
48. Stapp JR, Jelacic S, Yea YL et al. Comparison of Escherichia coli O157:H7 antigen detection in stool and broth cultures to that in sorbitol-MacConkey agar stool cultures. J. Clin. Microbiol. 38, 3404-3406 (2000).
49. Darrow DC, Pratt EL, Flett J et al. Disturbances of water and electrolytes in infantile diarrhea. Pediatrics 3, 129-156 (1949).
50. Harrison HE. The treatment of diarrhea of infancy. Pediatr. Clin. North Am. 1, 335-348 (1954).
51. Armon K, Stephenson T, MacFaul R, Eccleston P, Werneke U. An evidence and consensus based guideline for acute diarrhea management. Arch. Dis. Child. 85, 132-142 (2001)
52. Murphy MS. Guidelines for managing acute gastroenteritis based on a systematic review of published research. Arch. Dis. Child. 79, 279-284 (1998).
53. American Academy of Pediatrics, Provisional Committee on Quality Improvement Subcommittee on Acute Gastroenteritis. Practice parameter: the management of acute gastroenteritis in young children. Pediatrics 97, 424-436 (1996).
54. Nelson JD, Kusmiesz H, Jackson LH, Woodman E. Treatment of Salmonella gastroenteritis with ampicillin, amoxicillin, or placebo. Pediatrics 65, 1125-1130 (1980).
55. Chiu CH, Wu TL, Su LH et al. The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype choleraesuis. N. Engl. J. Med. 346, 413-419 (2002).
56. Chiu CH, Su LH, Chu C et al. Isolation of Salmonella enterica serotype choleraesuis resistant to ceftriaxone and ciprofloxacin. Lancet 363, 1285-1286 (2004).
57. Su LH, Chiu CH, Chu C, Ou JT. Antimicrobial resistance in nontyphoid Salmonella serotypes: a global challenge. Clin. Infect. Dis. 39, 546-551 (2004).
58. Su LH, Wu TL, Chia JH, Chu C, Kuo AJ, Chiu CH. Increasing ceftriaxone resistance in Salmonella isolates from a university hospital in Taiwan. J. Antimicrob. Chemother. 55, 846-852 (2005).
59. Mølbak K, Baggesen DL, Aarestrup FM et al. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104. N. Engl. J. Med. 341, 1420-1425 (1999).
60. Tauxe RV, Puhr ND, Wells JG, Hargrett-Bean N, Blake PA. Antimicrobial resistance of Shigella isolates in the USA: the importance of international travelers. J. Infect. Dis. 162, 1107-1111 (1990).
61. Kotloff KL, Winickoff JP, Ivanoff B et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. World Health Organ. 77, 651-666 (1999).
62. Williams MD, Schorling JB, Barrett LJ et al. Early treatment of Campylobacter jejuni enteritis. Antimicrob. Agents Chemother. 33, 248-250 (1989).
63. Nataro JP. Treatment of bacterial enteritis. Pediatr. Infect. Dis. J. 17, 420-421 (1998).
64. Helms M, Simonsen J, Olsen KE, Molbak K. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. J. Infect. Dis. 191, 1050-1055 (2005).
65. Ge B, Mc Dermott PF, White DG, Meng J. Role of efflux pumps and topoisomerase mutations in fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob. Agents Chemother. 49, 3347-3354 (2005).
66. Nelson JD. Duration of neomycin for enteropathogenic Escherichia coli diarrheal disease: a comparative study of 113 cases. Pediatrics 48, 248-258 (1971).
67. Thoren AL. Antibiotic sensitivity of enteropathogenic Escherichia coli to mecillinam, trimethoprim-sulfamethoxazole and other antibiotics. Acta Pathol. Microbiol. Scand. 88, 265-268 (1980).
68. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 288, 996-1001 (2002).
69. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342, 1930-1936 (2002).
70. Kimmitt PT. Harwood CR. Barer MR. Toxin gene expression by Shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg. Infect. Dis. 6, 458-465 (2000).
71. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, Acheson DW. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis. 181, 664-670 (2000).
72. Proulx F, Turgeon JP, Delage G, Lafleur L, Chicoine L. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J. Pediatr. 121(2), 299-303 (1992).
73. Carter AO, Borczyk AA, Carlson JA et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N. Engl. J. Med. 317, 1496-1500 (1987).
74. Gayraud M, Scavizzi MR, Mollaret HH, Guillevin L, Hornstein MJ. Antibiotic treatment of Yersinia enterocolitica septicemia: a retrospectives review of 43 cases. Clin. Infect. Dis. 17, 405-410 (1993).
75. Abdel-Haq NM, Asmar BI, Abuhammour WM, Brown WJ. Yersinia enterocolitica infection in children. Pediatr. Infect. Dis. J. 19, 954-958 (2000).
76. Walker WA, Goulet OJ, Kleinman RE, Sherman RM, Shneider BL, Sanderson IR. Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis, Management, 4th Edition. B.C. Decker Inc., NY, USA (2004).
77. Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can. Med. Assoc. J. 171, 466-472 (2004).
78. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J. Clin. Gastroenterol. 38, 414-418 (2004).
79. Kaper JB, Morris JG Jr, Levine MM. Cholera, Clin. Microbiol. Rev. 8(1), 48-86 (1995).
80. Krishna BV, Patil AB, Chandrasekhar MR. Fluoroquinolone-resistant Vibrio cholerae isolated during a cholera outbreak in India. Trans. R. Soc. Trop. Med. Hyg. 100, 224-226 (2006).
81. Arvola T, Laiho K, Torkkeli S et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 104, e64 (1999).
82. Lievin-Le Moal V, Amsellem R, Servin AL, Coconnier MH. Lactobacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyre-like cells. Gut 50, 803-811 (2002).
83. Shu Q, Qu F, Gill HS. Probiotic treatment using Bifidobacterium lactis HN019 reduces weanling diarrhea associated with rotavirus and Escherichia coli infection in a piglet model. J. Pediatr. Gastroenterol. Nutr. 33, 171-177 (2001).